JNJ catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 19, 2026Sponsor estimate | NCT07230860A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisJanssen Research & Development, LLC · Dermatitis, Atopic | JNJLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT03655223Early Check: Expanded Screening in NewbornsRTI International · Spinal Muscular Atrophy | SRPTCollaboratorJNJCollaboratorILMNCollaborator | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 19, 2026Sponsor estimatePhase 2NCT07230860A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisJanssen Research & Development, LLC · Dermatitis, AtopicActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT03655223Early Check: Expanded Screening in NewbornsRTI International · Spinal Muscular AtrophyActive, not recruitingSRPTCollaboratorJNJCollaboratorILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT00578240Molecular Studies and Clinical Correlations in Human Prostatic DiseaseMemorial Sloan Kettering Cancer Center · Prostate CancerActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04009109Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMAlliance Foundation Trials, LLC. · Myeloma, MultipleActive, not recruitingBMYCollaboratorTAKCollaboratorJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT04165564DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive BiomarkersBoston University · Pulmonary DiseaseActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT06062537Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma PatientsIntergroupe Francophone du Myelome · Multiple MyelomaActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 3NCT03767244A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical...Janssen Research & Development, LLC · Prostatic NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 1NCT04644770A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 3NCT05757869A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationJanssen Research & Development, LLC · Atrial FibrillationActive, not recruitingJNJLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2026Sponsor estimateNo phase registeredNCT02808780An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative ColitisJanssen Biotech, Inc. · Ulcerative ColitisActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2026Sponsor estimatePhase 2NCT06544616A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseJanssen Pharmaceutica N.V., Belgium · Alzheimer DiseaseActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT04658862A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder...Janssen Research & Development, LLC · Urinary Bladder NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT01804686A Long-term Extension Study of PCI-32765 (Ibrutinib)Janssen Research & Development, LLC · Chronic Lymphocytic LeukemiaActive, not recruitingJNJLeadABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT02436707Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaCanadian Cancer Trials Group · LymphomaActive, not recruitingKPTIQCollaboratorJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT02609776Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerJanssen Research & Development, LLC · Non-Small-Cell Lung CancerActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT04662580ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerJanssen Research & Development, LLC · Metastatic Prostate CancerActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 2027Sponsor estimatePhase 2NCT04270175Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabWeill Medical College of Cornell University · AmyloidActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT05666700CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring StudyPeter MacCallum Cancer Centre, Australia · Extramedullary MyelomaActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimatePhase 2NCT03902951Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerJonsson Comprehensive Cancer Center · Metastatic Prostate AdenocarcinomaActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2027Sponsor estimatePhase 1NCT05784441A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)Janssen Research & Development, LLC · Relapsed or Refractory B Cell Non-Hodgkin LymphomaActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 3NCT05047172Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular AtherostenosisUniversity of Florida · Intracranial ArteriosclerosisActive, not recruitingAZNCollaboratorJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 1/Phase 2NCT05908734A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerJanssen Research & Development, LLC · Carcinoma, Non-Small-Cell LungActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT04268498A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaUniversity of Miami · Multiple Myeloma | JNJCollaboratorAMGNCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Feb 4, 2027Sponsor estimate | NCT06741969Nipocalimab in Moderate to Severe Sjogren's DiseaseJanssen Research & Development, LLC · Sjogrens Syndrome | JNJLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Feb 10, 2027Sponsor estimate | NCT06260163A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisJanssen Research & Development, LLC · Colitis, Ulcerative | JNJLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 2NCT04268498A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaUniversity of Miami · Multiple MyelomaActive, not recruitingJNJCollaboratorAMGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 4, 2027Sponsor estimatePhase 3NCT06741969Nipocalimab in Moderate to Severe Sjogren's DiseaseJanssen Research & Development, LLC · Sjogrens SyndromeActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2027Sponsor estimatePhase 3NCT06260163A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisJanssen Research & Development, LLC · Colitis, UlcerativeActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 2 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.